Literature DB >> 26854432

Emerging therapies targeting castration-resistant prostate cancer.

Ioannis K Gkialas1, Charalampos Fragkoulis.   

Abstract

PURPOSE: Building on decades of research, the past few years have yielded a near expo-nential increase in treatment modalities for patients with metastatic prostate cancer. Individually, these improvements in overall survival may appear modest, however, nearly all of them have a distinct mechanism of action and the possibility of synergistic effects have yet to be established. The promise of a durable impact on the mortality from metastatic prostate cancer will likely stem from further elucidation of molecular pathways involved in prostate cancer, as well as defining the optimal sequence of treatment for patients with metastatic prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26854432

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  1 in total

1.  Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.

Authors:  Chun-Lin Pu; Jiu-Zhi Li; Wen-Long Fan
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.